CLC bio is expanding the distribution of its next-generation sequencing solutions into the Japanese market through a deal with Filgen. “In 2009, we have experienced a considerable increase of interest in our solutions from Japan,” according to director of partner sales at CLC bio, Michael Heltzen.

“This is logically linked with the significant increase of next-generation sequencing instruments being installed, which in turn requires analysis capacity of the huge amounts of data, an area where we excel. We regard the Japanese life science sector as one of the premier markets in Asia and are happy to announce this setup, so we can support our current and upcoming customers in Japan in the best possible way.”

Previous articleScripps-Led Consortium that Combines Physics and Oncology Receives $10M
Next articlePPD to Spin Out Compound-Partnering Segment, Acquire Chinese CRO, and Invest $100M in Celtic Therapeutics